Big Buttons

• HIPAA, schmipaa — Lilly is at it again

  Now Eli Lilly is trying to "convince" people who have used compounded versions of tirzepatide to share their confidential medical records with the company. read more →

• Settlement reached in Evexias suit against FDA

  A settlement has been reached in a lawsuit brought by Evexias et al against FDA over the agency's 2023 addition of a number of substances to Category 2 of the 503A bulks list. read more →

• Rochefort receives Malmberg Award

  David Rochefort of Revelation Pharma is this year's recipient of the George and Lucy Malmberg Compounding Advocacy Champion award — APC’s highest honor. read more →

• For they’re jolly good Fellows*

  This year’s CCH featured the induction of seven new APC fellows. read more →

• Be fruitful and multiply … our messaging, that is

  Even if you didn't attend Compounders on Capitol Hill, you can multiply the effect of those Hill visits. read more →

• APC supports upcoming DEA guidance on constructive transfer

  Some good news: DEA is set to issue much-needed new guidance on constructive transfer. read more →

• 503Bs: FDA has questions, and so do we (do you?)

  FDA has requested comments on the challenges and opportunities faced by compounding outsourcing facilities. read more →

• Meet our compounding defenders, guardians and champions (Oh my!)

  Here’s a big thank you to our Package Deal investors.  read more →

More News

FDA has requested comments on the challenges and opportunities faced by compounding outsourcing facilities. APC is planning to respond before the November 4 deadline, but we need to know your thoughts and pain points. If you have specific concerns you want to make sure we include in our comments, reach out to Tenille Davis at tenille@a4pc.org or Savannah Cunningham at savannah@a4pc.org.